Lyell Immunopharma, Inc. (LYEL) › Cash & EquivalentsLyell Immunopharma, Inc. (LYEL) — Cash & EquivalentsAnnual figures by period end, from SEC filings.2019-12-31: $96.67M2020-12-31: $140.41M2021-12-31: $293.83M2022-12-31: $123.55M2023-12-31: $145.65M2024-12-31: $105.60M2025-12-31: $60.18M$60.18M2019-12-31Cash & Equivalents (USD)2025-12-31Period endedCash & EquivalentsChange YoYSource filing2025-12-31$60.18M-43.0%2026-03-12Balance as of period end2024-12-31$105.60M-27.5%2026-03-12Balance as of period end2023-12-31$145.65M+17.9%2026-03-12Balance as of period end2022-12-31$123.55M-58.0%2025-03-11Balance as of period end2021-12-31$293.83M+109.3%2024-02-28Balance as of period end2020-12-31$140.41M+45.2%2023-02-28Balance as of period end2019-12-31$96.67M—2022-03-29Balance as of period endOther metrics: RevenueCost of RevenueGross ProfitOperating IncomeNet IncomeEPS (Diluted)Total AssetsTotal LiabilitiesShareholders' EquityOperating Cash FlowCapital ExpendituresShares OutstandingDividends Per ShareWeighted Average Diluted SharesEPS (Basic)